|
Orthologous residues
|
|
claspin (human): S30‑p, claspin (mouse): S30‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PLK1 (human)
|
transfection of dominant-negative enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
UV
|
|
|
|
decrease
|
|
|
hydroxyurea
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation, protein degradation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
BTRC (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
claspin degradation is necessary for termination of the DNA replication checkpoint.
|